Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 129 articles: HTML format

Single Articles

April 2026
1. LIANG S, Wang Q, Zhang M, Song X, et al
   A tumor-derived mitochondrial tsRNA drives vascular invasion of lung adenocarcinoma by promoting ribosomal assembly in endothelial cells.
   Cancer Lett. 2026;644:218324.
   PubMed     Abstract available
   
   
   
2. ARBEL R, Rokach L, Razi T, Tadmor T, et al
   Validation of "SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade" in an independent cohort of 4,407 patients.
   Cancer Lett. 2026;643:218319.
   PubMed     Abstract available
   
   
   
3. YANG J, Yu H, Zhong C, Xu L, et al
   Liver cancer-derived exosomal PTK6 induces the secretion of pulmonary CHI3L1 to facilitate lung metastatic niche formation.
   Cancer Lett. 2026;643:218312.
   PubMed     Abstract available
   
   
   
4. WANG H, Tian X, Zhu W, Wang Y, et al
   ZBTB20 promotes malignancy and stemness in lung squamous cell carcinoma through the transcriptional repression of KCTD1 and activation of Hedgehog signaling.
   Cancer Lett. 2026;643:218301.
   PubMed     Abstract available
   
   
   
5. LIU D, Liu B, Yang R, Song J, et al
   Targeting Galectin-9 to overcome immunosuppression and potentiate ATR inhibitor therapy.
   Cancer Lett. 2026;643:218283.
   PubMed     Abstract available
   
   
   March 2026
6. YANG Y, Liu C, Yang L, Zheng S, et al
   IL-6 drives chemoimmunotherapy resistance in NSCLC by reprogramming myeloid cells and impairing cytotoxic lymphocyte function.
   Cancer Lett. 2026;641:218259.
   PubMed     Abstract available
   
   
   February 2026
7. DONG X, Li R, Yao X, Li Y, et al
   Strategies to optimize duration of immunotherapy in advanced NSCLC: Current evidence and future directions.
   Cancer Lett. 2026;639:218203.
   PubMed     Abstract available
   
   
   
8. APPADURAI MI, Alsafwani ZW, Chaudhary S, Shah A, et al
   Ixazomib triggers autophagic degradation of MUC5AC/integrin-beta4 and inhibits non-small cell lung cancer progression.
   Cancer Lett. 2026 Feb 28:218333. doi: 10.1016/j.canlet.2026.218333.
   PubMed     Abstract available
   
   
   
9. YAN JS, Wang YZ, Zhao SY, Na FJ, et al
   Immunotherapy for extensive-stage small cell lung cancer: current status, challenges and future strategies.
   Cancer Lett. 2026;645:218382.
   PubMed     Abstract available
   
   
   
10. CHEN Y, Xing H, Yang X, Shen J, et al
    Patient-derived malignant effusion organoids guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms in lung cancer.
    Cancer Lett. 2026;645:218356.
    PubMed     Abstract available
    
    
    
11. YANG J, Zhang M, Gao C, Yao X, et al
    The Histone-Modified Landscape: Core Mechanisms of Osimertinib Resistance in EGFR-Mutant Lung Cancer.
    Cancer Lett. 2026 Feb 19:218321. doi: 10.1016/j.canlet.2026.218321.
    PubMed     Abstract available
    
    
    
12. HU S, Zhao Z, Zhao J, Liang Y, et al
    Protein kinase Ciota-driven macrophage infiltration mediates immunosuppression in non-small cell lung cancer.
    Cancer Lett. 2026 Feb 18:218330. doi: 10.1016/j.canlet.2026.218330.
    PubMed     Abstract available
    
    
    
13. XU Z, Gao J, Ye C, Li Y, et al
    PPP4C restores YAP1 activity by modulating MST4 phosphorylation to enhance immunosuppression and augment tumor growth in non-small cell lung cancer.
    Cancer Lett. 2026 Feb 12:218306. doi: 10.1016/j.canlet.2026.218306.
    PubMed     Abstract available
    
    
    January 2026
14. SHEN A, Zheng S, Tang X, Yao Y, et al
    Integrated multi-omics analyses identified the H3K18la-based spatiotemporal characteristics and risk-stratified treatment strategy in lung adenocarcinoma.
    Cancer Lett. 2026;638:218158.
    PubMed     Abstract available
    
    
    
15. HUANG Y, Wei Z, Ye G, Cui Y, et al
    Automated CT-derived Body Composition Predicts Pathologic Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
    Cancer Lett. 2026 Jan 6:218229. doi: 10.1016/j.canlet.2025.218229.
    PubMed     Abstract available
    
    
    
16. LI Y, Li C, Wang Y, Zhou J, et al
    Mitigating tumor heterogeneity in lung Cancer: A dual-targeted NIR-II imaging strategy for accurate tumor localization and intraoperative navigation.
    Cancer Lett. 2026;640:218241.
    PubMed     Abstract available
    
    
    
17. WANG P, Tang HXL, Song J, Yang Y, et al
    Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib.
    Cancer Lett. 2026;636:218100.
    PubMed     Abstract available
    
    
    December 2025
18. MENG X, Bi N, Wang J, Meng X, et al
    Consensus on the Diagnosis and Treatment of Unresectable Stage III Driver Gene-Positive Non-Small Cell Lung Cancer.
    Cancer Lett. 2025 Dec 17:218223. doi: 10.1016/j.canlet.2025.218223.
    PubMed     Abstract available
    
    
    
19. WU F, Shen J, Zhao Z, Chen Y, et al
    HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8(+) T cell glutamine metabolism via KIR3DL3 interaction.
    Cancer Lett. 2025;639:218219.
    PubMed     Abstract available
    
    
    
20. ZHANG WY, Wang ZQ, Fan XX
    Overcoming EGFR TKI Resistance and Immunosuppression in Non-Small Cell Lung Cancer via EGFR/TLR9/PD-L1 Triple-Targeted Therapy.
    Cancer Lett. 2025 Dec 10:218217. doi: 10.1016/j.canlet.2025.218217.
    PubMed    
    
    
    
21. GAO Y, Li LX, Rowland A, Karapetis CS, et al
    Progressive Lesion Type is Predictive of Post-progression Survival in First-line Chemoimmunotherapy for Non-small Cell Lung Cancer.
    Cancer Lett. 2025 Dec 10:218191. doi: 10.1016/j.canlet.2025.218191.
    PubMed    
    
    
    
22. HUANG X, Liang J, Yi Y, Zhu J, et al
    Targeting inosine metabolism to enhance EGFR-targeted therapy in lung adenocarcinoma.
    Cancer Lett. 2025;634:218069.
    PubMed     Abstract available
    
    
    
23. XIAO C, Fan T, Wang D, Yin H, et al
    RAD21-mediated epigenetic regulation promotes lung adenocarcinoma progression and sensitizes cancer cells to ERK-targeted therapy.
    Cancer Lett. 2025;634:218062.
    PubMed     Abstract available
    
    
    
24. KUANG Y, Yang S, Tian X, Cheng H, et al
    Hinokitiol preferentially suppresses metastatic lung adenocarcinoma via TMDD1-mediated ferroptosis induction and iron-sulfur cluster inhibition.
    Cancer Lett. 2025;634:218046.
    PubMed     Abstract available
    
    
    November 2025
25. SHE L, Chen J, Liu JY, Liu JS, et al
    A two-stage genome-wide association study to identify novel genetic loci associated with irAEs in lung cancer patients received PD-1/PD-L1 inhibitors.
    Cancer Lett. 2025 Nov 22:218168. doi: 10.1016/j.canlet.2025.218168.
    PubMed     Abstract available
    
    
    
26. KHAN MA, Khan P, Fatima M, Rehman AU, et al
    Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression.
    Cancer Lett. 2025;638:218160.
    PubMed     Abstract available
    
    
    
27. LIU Y, Prasad CB, Qiu Z, Singh D, et al
    CD40 drives tumor growth in non-small cell lung cancer via non-canonical immune-independent mechanisms.
    Cancer Lett. 2025;637:218151.
    PubMed    
    
    
    
28. WANG G, Wang W
    Letter to the editor on 'AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional study'.
    Cancer Lett. 2025;636:218107.
    PubMed    
    
    
    October 2025
29. XU Y, Chen M, Gao X, Liu X, et al
    Efficacy and safety of sunvozertinib monotherapy as first-line treatment in NSCLC patients with EGFR exon 20 insertion mutations: A phase 2, single-center trial.
    Cancer Lett. 2025;630:217904.
    PubMed     Abstract available
    
    
    
30. ZADRA I, Abad E, Krasko A, Porqueras VC, et al
    A novel mismatch repair deficient lung adenocarcinoma model for immunotherapy research.
    Cancer Lett. 2025;629:217882.
    PubMed     Abstract available
    
    
    September 2025
31. JIA W, Ma L, Bai M, Li J, et al
    Loss of ADAR1 in lung cancer activates anti-tumour immunity and suppresses tumour cell growth via the RIG-I/MDA5-MAVS pathway.
    Cancer Lett. 2025 Sep 30:218071. doi: 10.1016/j.canlet.2025.218071.
    PubMed     Abstract available
    
    
    
32. LI X, Liu K, Zhang Z, Zhu W, et al
    Targeting the cholinergic-astrocyte axis: A novel strategy for brain metastasis prevention in lung adenocarcinoma.
    Cancer Lett. 2025;628:217870.
    PubMed     Abstract available
    
    
    
33. CHEN Y, Wang X, Li H, Zhang Z, et al
    Oncoprotein SND1-enriched exosomes facilitate melanoma lung metastasis by regulating CD47-SIRPalpha-mediated macrophage reprogramming.
    Cancer Lett. 2025 Sep 25:218037. doi: 10.1016/j.canlet.2025.218037.
    PubMed     Abstract available
    
    
    
34. JIANG C, He X, Chen X, Huang J, et al
    Lactate accumulation drives hepatocellular carcinoma metastasis through facilitating tumor-derived exosome biogenesis by Rab7A lactylation.
    Cancer Lett. 2025;627:217636.
    PubMed     Abstract available
    
    
    August 2025
35. CHEN Z, Vallega KA, Wang D, Bildtsen E, et al
    Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer.
    Cancer Lett. 2025;633:218010.
    PubMed     Abstract available
    
    
    
36. YANG Y, Li Z, Yu X, Zheng Y, et al
    WDR11-DT enhances radiosensitivity via promoting PARP1 degradation and homologous recombination deficiency.
    Cancer Lett. 2025;625:217757.
    PubMed     Abstract available
    
    
    July 2025
37. MA G, Wang D, Deng Y, Huang W, et al
    Targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition to delay emergence of acquired resistance of lung cancer to osimertinib.
    Cancer Lett. 2025;632:217962.
    PubMed     Abstract available
    
    
    
38. LUCA AC, Kurnaeva M, John DK, Machtinger M, et al
    Loss of SPHK1 fuels inflammation to drive KRAS-mutated lung adenocarcinoma.
    Cancer Lett. 2025;623:217733.
    PubMed     Abstract available
    
    
    
39. JIANG M, Zhang K, Wei G, Qi F, et al
    HDAC4 super-enhancer drives CEBPB-mediated TWIST2 transcription to promote chemoresistance in LUAD.
    Cancer Lett. 2025;623:217716.
    PubMed     Abstract available
    
    
    June 2025
40. HUANG Y, Song J, Chen J, Li F, et al
    The significance of protein N-glycosylation in the pathogenesis of lung cancer and its clinical implications.
    Cancer Lett. 2025 Jun 25:217849. doi: 10.1016/j.canlet.2025.217849.
    PubMed     Abstract available
    
    
    
41. CHEN H, Yu G, Lin H, Zhou XA, et al
    Loss of FTSJ3 promotes R-loop-associated DNA damage and facilitates chemosensitivity in lung cancer cells.
    Cancer Lett. 2025 Jun 13:217877. doi: 10.1016/j.canlet.2025.217877.
    PubMed     Abstract available
    
    
    
42. KHORRAMI M, Mutha P, Barrera C, Viswanathan VS, et al
    AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional study.
    Cancer Lett. 2025;628:217872.
    PubMed     Abstract available
    
    
    May 2025
43. WADE WEI TY, Hsia JY, Yang TY, Huang YX, et al
    Mechanistic Insights into CLNS1A-Mediated Chemoresistance and Tumor Progression in Non-small Cell Lung Cancer.
    Cancer Lett. 2025 May 7:217783. doi: 10.1016/j.canlet.2025.217783.
    PubMed     Abstract available
    
    
    April 2025
44. JIANG J, Chen H, Zhao C, Li T, et al
    PRTN3 promotes IL33/Treg-mediated tumor immunosuppression by enhancing the M2 polarization of tumor-associated macrophages in lung adenocarcinoma.
    Cancer Lett. 2025;616:217584.
    PubMed     Abstract available
    
    
    
45. LIN H, Hua J, Gong Z, Chen M, et al
    Multimodal radiopathological integration for prognosis and prediction of adjuvant chemotherapy benefit in resectable lung adenocarcinoma: A multicentre study.
    Cancer Lett. 2025;616:217557.
    PubMed     Abstract available
    
    
    
46. MO Y, Qin Y, Li P, Wu M, et al
    Thyroxine alleviates interstitial lung disease induced by combined radiotherapy and immunotherapy.
    Cancer Lett. 2025;615:217504.
    PubMed     Abstract available
    
    
    
47. XIAO X, Huang L, Li M, Zhang Q, et al
    Intersection between lung cancer and neuroscience: opportunities and challenges.
    Cancer Lett. 2025 Apr 5:217701. doi: 10.1016/j.canlet.2025.217701.
    PubMed     Abstract available
    
    
    March 2025
48. PENG X, Yang R, Wang C, Peng W, et al
    The YTHDF3-DT/miR-301a-3p /INHBA axis attenuates autophagy-dependent ferroptosis in lung adenocarcinoma.
    Cancer Lett. 2025;613:217503.
    PubMed     Abstract available
    
    
    
49. LI J, Xu S, Zhan Y, Lv X, et al
    CircRUNX1 enhances the Warburg effect and immune evasion in non-small cell lung cancer through the miR-145/HK2 pathway.
    Cancer Lett. 2025 Mar 14:217639. doi: 10.1016/j.canlet.2025.217639.
    PubMed     Abstract available
    
    
    
50. ZHAO L, Ren Y, Gong C, Xiong S, et al
    RMethyMD: An integrated platform for exploring RNA methylation in pan-cancer via a multiomics analysis.
    Cancer Lett. 2025;612:217462.
    PubMed     Abstract available
    
    
    
51. TANG X, Hu J, Guo R, Wang Y, et al
    RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs.
    Cancer Lett. 2025;612:217455.
    PubMed     Abstract available
    
    
    February 2025
52. FU R, Zhang C, Song MM, Gao X, et al
    A single-cell map of patients with non-small cell lung cancer harboring rare-driver mutations after anti-PD-1 treatment.
    Cancer Lett. 2025;616:217595.
    PubMed     Abstract available
    
    
    January 2025
53. HUANG M, Sun J, Jiang Q, Zhao X, et al
    CircKIAA0182-YBX1 Axis: A Key Driver of Lung Cancer Progression and Chemoresistance.
    Cancer Lett. 2025;612:217494.
    PubMed     Abstract available
    
    
    December 2024
54. YU JJ, Zhou DD, Cui B, Zhang C, et al
    Corrigendum to <[ Cancer Letters 474 (2020) 23-35]>.
    Cancer Lett. 2024 Dec 30:217434. doi: 10.1016/j.canlet.2024.217434.
    PubMed    
    
    
    
55. DONG XD, Zhang M, Teng QX, Lei ZN, et al
    Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies.
    Cancer Lett. 2024;607:217309.
    PubMed     Abstract available
    
    
    
56. HUANG S, Chung JY, Li C, Wu Y, et al
    Corrigendum to "Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma" [Cancer Lett. 604 (2024) 217272].
    Cancer Lett. 2024 Dec 27:217425. doi: 10.1016/j.canlet.2024.217425.
    PubMed    
    
    
    
57. YAMAMOTO G, Tanaka K, Kamata R, Saito H, et al
    WEE1 Confers Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer.
    Cancer Lett. 2024 Dec 24:217414. doi: 10.1016/j.canlet.2024.217414.
    PubMed     Abstract available
    
    
    
58. SUAY G, Garcia-Canaveras JC, Aparisi F, Garcia J, et al
    Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations.
    Cancer Lett. 2024;606:217317.
    PubMed     Abstract available
    
    
    
59. NERLAKANTI N, McGuire JJ, Bishop RT, Nasr MM, et al
    Histone deacetylase upregulation of neuropilin-1 in osteosarcoma is essential for pulmonary metastasis.
    Cancer Lett. 2024;606:217302.
    PubMed     Abstract available
    
    
    November 2024
60. LI J, Wang X, Cao G, Wu Y, et al
    CD94 deficiency or blockade unleashes the anti-tumor immunity in mice and humanized murine models.
    Cancer Lett. 2024;605:217305.
    PubMed     Abstract available
    
    
    
61. ZHAO Y, Zhang D, Meng B, Zhang Y, et al
    Integrated proteomic and glycoproteomic analysis reveals heterogeneity and molecular signatures of brain metastases from lung adenocarcinomas.
    Cancer Lett. 2024;605:217262.
    PubMed     Abstract available
    
    
    
62. GE H, Malsiu F, Gao Y, Losmanova T, et al
    Inhibition of LDHB suppresses the metastatic potential of lung cancer by reducing mitochondrial GSH catabolism.
    Cancer Lett. 2024 Nov 28:217353. doi: 10.1016/j.canlet.2024.217353.
    PubMed     Abstract available
    
    
    
63. ZHANG J, Wu Q, Zhu L, Xie S, et al
    Corrigendum to "SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer" [Cancer Lett. 524 (2022) 268-283].
    Cancer Lett. 2024 Nov 23:217337. doi: 10.1016/j.canlet.2024.217337.
    PubMed    
    
    
    October 2024
64. PLAUGHER DR, Childress AR, Gosser CM, Esoe DP, et al
    Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer.
    Cancer Lett. 2024 Oct 4:217281. doi: 10.1016/j.canlet.2024.217281.
    PubMed     Abstract available
    
    
    
65. WU J, Chen Y, Zou H, Xu K, et al
    6-Phosphogluconate dehydrogenase promotes glycolysis and fatty acid synthesis by inhibiting the AMPK pathway in lung adenocarcinoma cells.
    Cancer Lett. 2024;601:217177.
    PubMed     Abstract available
    
    
    September 2024
66. HUANG L, Liu X, Chen Q, Yang J, et al
    TGF-beta-induced lncRNA TBUR1 promotes EMT and metastasis in lung adenocarcinoma via hnRNPC-mediated GRB2 mRNA stabilization.
    Cancer Lett. 2024;600:217153.
    PubMed     Abstract available
    
    
    
67. WU J, Zhao Q, Chen S, Xu H, et al
    NSUN4-mediated m5C modification of circERI3 promotes lung cancer development by altering mitochondrial energy metabolism.
    Cancer Lett. 2024 Sep 25:217266. doi: 10.1016/j.canlet.2024.217266.
    PubMed     Abstract available
    
    
    
68. HUANG S, Yat-Fai Chung J, Li C, Wu Y, et al
    Cellular Dynamics of Tumor Microenvironment Driving Immunotherapy Resistance in Non-Small-Cell Lung Carcinoma.
    Cancer Lett. 2024 Sep 24:217272. doi: 10.1016/j.canlet.2024.217272.
    PubMed     Abstract available
    
    
    
69. GARGALIONIS AN, Papavassiliou KA, Basdra EK, Papavassiliou AG, et al
    Exploiting tumor mechanomedicine for lung cancer treatment.
    Cancer Lett. 2024;604:217229.
    PubMed    
    
    
    
70. GANG X, Yan J, Li X, Shi S, et al
    Immune Checkpoint Inhibitors Rechallenge in Non-Small Cell Lung Cancer: Current Evidence and Future Directions.
    Cancer Lett. 2024 Sep 9:217241. doi: 10.1016/j.canlet.2024.217241.
    PubMed     Abstract available
    
    
    
71. LA VECCHIA S, Fontana S, Salaroglio IC, Anobile DP, et al
    Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy.
    Cancer Lett. 2024;604:217221.
    PubMed     Abstract available
    
    
    
72. WEI X, Uchibori K, Kondo N, Utsumi T, et al
    MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.
    Cancer Lett. 2024 Sep 5:217220. doi: 10.1016/j.canlet.2024.217220.
    PubMed     Abstract available
    
    
    
73. SUN SY
    Is tumor microenvironment important for targeted therapy in lung cancer?
    Cancer Lett. 2024 Sep 3:217203. doi: 10.1016/j.canlet.2024.217203.
    PubMed    
    
    
    
74. XUE R, Li X, Yang L, Yang M, et al
    Evaluation and integration of cell-free DNA signatures for detection of lung cancer.
    Cancer Lett. 2024 Sep 2:217216. doi: 10.1016/j.canlet.2024.217216.
    PubMed     Abstract available
    
    
    August 2024
75. LI J, Bai M, Jia W, Zhai X, et al
    Irradiated tumor cell-released microparticles enhance the therapeutic efficacy of PD-1 inhibitors by promoting M1-TAMs polarization in NSCLC brain metastases.
    Cancer Lett. 2024;598:217133.
    PubMed     Abstract available
    
    
    
76. LU Y, Sun Y, Zhang J, Kong M, et al
    The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants.
    Cancer Lett. 2024;596:217020.
    PubMed     Abstract available
    
    
    
77. FLETCHER K, Cortellini A, Ganta T, Kankaria R, et al
    Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
    Cancer Lett. 2024;596:217001.
    PubMed     Abstract available
    
    
    
78. KIM YJ, Lee M, Kim EH, Lee S, et al
    Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
    Cancer Lett. 2024;596:216998.
    PubMed     Abstract available
    
    
    
79. CHOW Z, Johnson J, Chauhan A, Jeong JC, et al
    Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
    Cancer Lett. 2024;596:216993.
    PubMed     Abstract available
    
    
    July 2024
80. HUANG L, Wang J, Wang X, Zheng S, et al
    Sulforaphane suppresses bladder cancer metastasis via blocking actin nucleation-mediated pseudopodia formation.
    Cancer Lett. 2024 Jul 29:217145. doi: 10.1016/j.canlet.2024.217145.
    PubMed     Abstract available
    
    
    
81. LIU M, Gu L, Zhang Y, Li Y, et al
    LKB1 inhibits telomerase activity resulting in cellular senescence through histone lactylation in lung adenocarcinoma.
    Cancer Lett. 2024;595:217025.
    PubMed     Abstract available
    
    
    
82. NAKAMURA R, Yamada T, Tokuda S, Morimoto K, et al
    Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
    Cancer Lett. 2024;598:217124.
    PubMed     Abstract available
    
    
    
83. SINGH D, Qiu Z, Jonathan SM, Fa P, et al
    PP2A B55alpha Inhibits Epithelial-Mesenchymal Transition Via Regulation of Slug Expression in Non-Small Cell Lung Cancer.
    Cancer Lett. 2024 Jul 8:217110. doi: 10.1016/j.canlet.2024.217110.
    PubMed     Abstract available
    
    
    
84. LI X, Shang S, Wu M, Song Q, et al
    Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis.
    Cancer Lett. 2024;598:217096.
    PubMed     Abstract available
    
    
    
85. SHU M, Huang L, Chen Y, Wang Y, et al
    Identification of a DNA-methylome-based signature for prognosis prediction in driver gene-negative lung adenocarcinoma.
    Cancer Lett. 2024;593:216835.
    PubMed     Abstract available
    
    
    June 2024
86. GUGNONI M, Lorenzini E, Torricelli F, Donati B, et al
    Linc00941 fuels ribogenesis and protein synthesis by supporting robust cMYC translation in malignant pleural mesothelioma.
    Cancer Lett. 2024;592:216950.
    PubMed     Abstract available
    
    
    
87. HE Q, Qu M, Xu C, Wu L, et al
    Smoking-induced CCNA2 expression promotes lung adenocarcinoma tumorigenesis by boosting AT2/AT2-like cell differentiation.
    Cancer Lett. 2024;592:216922.
    PubMed     Abstract available
    
    
    
88. XU Z, Shi Y, Zhu L, Luo J, et al
    Novel SERCA2 inhibitor Diphyllin displays anti-tumor effect in non-small cell lung cancer by promoting endoplasmic reticulum stress and mitochondrial dysfunction.
    Cancer Lett. 2024 Jun 21:217075. doi: 10.1016/j.canlet.2024.217075.
    PubMed     Abstract available
    
    
    
89. GUO W, Qiao T, Li H, Zhao Y, et al
    Peripheral CD8(+)PD-1(+) T cells as novel biomarker for neoadjuvant chemoimmunotherapy in humanized mice of non-small cell lung cancer.
    Cancer Lett. 2024;597:217073.
    PubMed     Abstract available
    
    
    
90. LIU X, Zheng W, Zhang L, Cao Z, et al
    Corrigendum to "Arginine methylation-dependent cGAS stability promotes non-small cell lung cancer cell proliferation" [Cancer Lett. 586 (2024) 216707/CAN_216707].
    Cancer Lett. 2024 Jun 5:217003. doi: 10.1016/j.canlet.2024.217003.
    PubMed    
    
    
    
91. ZHENG L, Shen J, Chen Y, Lin J, et al
    FBXO43 promotes cell cycle progression in cancer cells through stabilizing SKP2.
    Cancer Lett. 2024;591:216848.
    PubMed     Abstract available
    
    
    May 2024
92. ZHANG L, Xu Y, Cheng Z, Zhao J, et al
    The EGR1/miR-139/NRF2 axis orchestrates radiosensitivity of non-small-cell lung cancer via ferroptosis.
    Cancer Lett. 2024;595:217000.
    PubMed     Abstract available
    
    
    
93. BOSSE Y, Dasgupta A, Abadier M, Guthrie V, et al
    Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer.
    Cancer Lett. 2024;594:216984.
    PubMed     Abstract available
    
    
    
94. JIANG Y, Li S, Ramesh R
    Identification of SMARCAL1 as a molecular target for small cell lung cancer treatment.
    Cancer Lett. 2024 May 10:216932. doi: 10.1016/j.canlet.2024.216932.
    PubMed    
    
    
    
95. CHEN X, Yuan M, Zhong T, Wang M, et al
    LILRB2 Inhibition Enhances Radiation Sensitivity in Non-Small Cell Lung Cancer by Attenuating Radiation-Induced Senescence.
    Cancer Lett. 2024 May 3:216930. doi: 10.1016/j.canlet.2024.216930.
    PubMed     Abstract available
    
    
    
96. WANG PS, Liu Z, Sweef O, Saeed AF, et al
    Hexavalent chromium exposure activates the non-canonical nuclear factor kappa B pathway to promote immune checkpoint protein programmed death-ligand 1 expression and lung carcinogenesis.
    Cancer Lett. 2024;589:216827.
    PubMed     Abstract available
    
    
    
97. YU T, Liu Z, Tao Q, Xu X, et al
    Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming.
    Cancer Lett. 2024;589:216824.
    PubMed     Abstract available
    
    
    
98. LUO S, Luo Y, Wang Z, Yin H, et al
    Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma.
    Cancer Lett. 2024;589:216811.
    PubMed     Abstract available
    
    
    April 2024
99. SUN BB, Wang GZ, Han SC, Yang FY, et al
    Oncogenic functions and therapeutic potentials of targeted inhibition of SMARCAL1 in small cell lung cancer.
    Cancer Lett. 2024 Apr 30:216929. doi: 10.1016/j.canlet.2024.216929.
    PubMed     Abstract available
    
    
    
100. YOKOTA E, Iwai M, Yukawa T, Naomoto Y, et al
     Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies.
     Cancer Lett. 2024;588:216816.
     PubMed     Abstract available
     
     
     
101. MOON JW, Hong BJ, Kim SK, Park MS, et al
     Systematic identification of a synthetic lethal interaction in brain-metastatic lung adenocarcinoma.
     Cancer Lett. 2024;588:216781.
     PubMed     Abstract available
     
     
     
102. LUO J, Cheng K, Ji X, Gao C, et al
     Anlotinib enhanced CD8(+) T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer.
     Cancer Lett. 2024;591:216892.
     PubMed     Abstract available
     
     
     
103. MORIMOTO K, Yamada T, Hirai S, Katayama Y, et al
     AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
     Cancer Lett. 2024;587:216692.
     PubMed     Abstract available
     
     
     
104. GAO GB, Chen L, Pan JF, Lei T, et al
     LncRNA RGMB-AS1 inhibits HMOX1 ubiquitination and NAA10 activation to induce ferroptosis in non-small cell lung cancer.
     Cancer Lett. 2024 Apr 2:216826. doi: 10.1016/j.canlet.2024.216826.
     PubMed     Abstract available
     
     
     
105. HAO Z, Xin Z, Chen Y, Shao Z, et al
     JAML promotes the antitumor role of tumor-resident CD8(+) T cells by facilitating their innate-like function in human lung cancer.
     Cancer Lett. 2024 Apr 1:216839. doi: 10.1016/j.canlet.2024.216839.
     PubMed     Abstract available
     
     
     March 2024
106. ZHANG E, Sun Q, Zhang C, Ma H, et al
     Comprehensive functional interrogation of susceptibility loci in GWASs identified KIAA0391 as a novel oncogenic driver via regulating pyroptosis in NSCLC.
     Cancer Lett. 2024;585:216646.
     PubMed     Abstract available
     
     
     
107. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
     Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
     Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
     PubMed     Abstract available
     
     
     
108. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
     Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
     Cancer Lett. 2024;584:216608.
     PubMed     Abstract available
     
     
     February 2024
109. HAN R, Lin C, Lu C, Wang Y, et al
     Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.
     Cancer Lett. 2024;588:216762.
     PubMed     Abstract available
     
     
     
110. LIU X, Zheng W, Zhang L, Cao Z, et al
     Arginine methylation-dependent cGAS stability promotes non-small cell lung cancer cell proliferation.
     Cancer Lett. 2024 Feb 6:216707. doi: 10.1016/j.canlet.2024.216707.
     PubMed     Abstract available
     
     
     
111. LU X, Yu R, Li Z, Yang M, et al
     JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.
     Cancer Lett. 2024;582:216517.
     PubMed     Abstract available
     
     
     
112. LIN S, He C, Song L, Sun L, et al
     Exosomal lncCRLA is predictive for the evolvement and development of lung adenocarcinoma.
     Cancer Lett. 2024;582:216588.
     PubMed     Abstract available
     
     
     
113. BISWAS U, Roy R, Ghosh S, Chakrabarti G, et al
     The interplay between autophagy and apoptosis: its implication in lung cancer and therapeutics.
     Cancer Lett. 2024 Feb 1:216662. doi: 10.1016/j.canlet.2024.216662.
     PubMed     Abstract available
     
     
     January 2024
114. SUN J, Dong M, Xiang X, Zhang S, et al
     Notch signaling and targeted therapy in non-small cell lung cancer.
     Cancer Lett. 2024 Jan 30:216647. doi: 10.1016/j.canlet.2024.216647.
     PubMed     Abstract available
     
     
     
115. SUI Q, Hu Z, Liang J, Lu T, et al
     Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect of metformin in treating lung adenocarcinoma.
     Cancer Lett. 2024;581:216497.
     PubMed     Abstract available
     
     
     
116. ZHANG H, Li S, Zhou R, Dong T, et al
     SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.
     Cancer Lett. 2024;585:216667.
     PubMed     Abstract available
     
     
     
117. ZHOU X, Jia Y, Mao C, Liu S, et al
     Small extracellular vesicles: Non-negligible vesicles in tumor progression, diagnosis, and therapy.
     Cancer Lett. 2024;580:216481.
     PubMed     Abstract available
     
     
     December 2023
118. YANG Y, Wang J, Wang J, Zhao X, et al
     Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer.
     Cancer Lett. 2023 Dec 13:216569. doi: 10.1016/j.canlet.2023.216569.
     PubMed     Abstract available
     
     
     
119. MENG Y, Lin W, Wang N, Wei X, et al
     USP7-mediated ERbeta stabilization mitigates ROS accumulation and promotes osimertinib resistance by suppressing PRDX3 SUMOylation in non-small cell lung carcinoma.
     Cancer Lett. 2023 Dec 12:216587. doi: 10.1016/j.canlet.2023.216587.
     PubMed     Abstract available
     
     
     
120. XIE Y, Zhang L, Wang L, Chen B, et al
     EphB1 promotes the differentiation and maturation of dendritic cells in non-small cell lung cancer.
     Cancer Lett. 2023;582:216567.
     PubMed     Abstract available
     
     
     
121. YUAN Y, Li Y, Wu X, Bo J, et al
     POH1 induces Smad3 deubiquitination and promotes lung cancer metastasis.
     Cancer Lett. 2023 Dec 5:216526. doi: 10.1016/j.canlet.2023.216526.
     PubMed     Abstract available
     
     
     
122. KONG R, Wei W, Man Q, Chen L, et al
     Hypoxia-induced circ-CDYL-EEF1A2 transcriptional complex drives lung metastasis of cancer stem cells from hepatocellular carcinoma.
     Cancer Lett. 2023;578:216442.
     PubMed     Abstract available
     
     
     November 2023
123. ZHOU Y, Guo Y, Ran M, Shan W, et al
     Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing.
     Cancer Lett. 2023;577:216425.
     PubMed     Abstract available
     
     
     
124. NAMKAEW J, Zhang J, Yamakawa N, Hamada Y, et al
     Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer.
     Cancer Lett. 2023 Nov 28:216509. doi: 10.1016/j.canlet.2023.216509.
     PubMed     Abstract available
     
     
     
125. CAI S, Zhang B, Huang C, Deng Y, et al
     CTRP6 protects against ferroptosis to drive lung cancer progression and metastasis by destabilizing SOCS2 and augmenting the xCT/GPX4 pathway.
     Cancer Lett. 2023;579:216465.
     PubMed     Abstract available
     
     
     
126. LI B, Chen Q, Feng Y, Wei T, et al
     Glucose restriction induces AMPK-SIRT1-mediated circadian clock gene Per expression and delays NSCLC progression.
     Cancer Lett. 2023;576:216424.
     PubMed     Abstract available
     
     
     October 2023
127. HUA WJ, Yeh H, Lin ZH, Tseng AJ, et al
     Ganoderma microsporum immunomodulatory protein as an extracellular epidermal growth factor receptor (EGFR) degrader for suppressing EGFR-positive lung cancer cells.
     Cancer Lett. 2023;578:216458.
     PubMed     Abstract available
     
     
     
128. ZHANG Q, Zheng L, Bai Y, Su C, et al
     ITPR1-AS1 promotes small cell lung cancer metastasis by facilitating P21(HRAS) splicing and stabilizing DDX3X to activate the cRaf-MEK-ERK cascade.
     Cancer Lett. 2023 Oct 9:216426. doi: 10.1016/j.canlet.2023.216426.
     PubMed     Abstract available
     
     
     September 2023
129. LIU X, Li R, Chen X, Yao J, et al
     SYT7 is a key player in increasing exosome secretion and promoting angiogenesis in non-small-cell lung cancer.
     Cancer Lett. 2023 Sep 27:216400. doi: 10.1016/j.canlet.2023.216400.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum